Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,735,565
  • Shares Outstanding, K 29,686
  • Annual Sales, $ 0 K
  • Annual Income, $ -76,850 K
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.35
Trade CRTX with:

Options Overview Details

View History
  • Implied Volatility 245.46%
  • Historical Volatility 59.87%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 245.46% on 09/24/21
  • IV Low 57.61% on 07/08/21
  • Put/Call Vol Ratio 0.61
  • Today's Volume 667
  • Volume Avg (30-Day) 636
  • Put/Call OI Ratio 2.88
  • Today's Open Interest 1,543
  • Open Int (30-Day) 1,484

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.92
  • Number of Estimates 2
  • High Estimate -0.70
  • Low Estimate -1.13
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -26.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.70 +14.63%
on 09/15/21
110.64 -15.36%
on 08/30/21
-2.08 (-2.17%)
since 08/24/21
3-Month
50.14 +86.78%
on 07/15/21
121.98 -23.23%
on 08/10/21
+34.99 (+59.65%)
since 06/24/21
52-Week
26.66 +251.26%
on 12/29/20
121.98 -23.23%
on 08/10/21
+45.46 (+94.33%)
since 09/24/20

Most Recent Stories

More News
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

--Clinical advancement of pipeline delivers on commitment to bring innovation to an increasing range of P. gingivalis-related disease indications with high unmet clinical needs

CRTX : 93.65 (+1.63%)
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 93.65 (+1.63%)
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer's Disease at Annual Biomarkers for Alzheimer's Disease Summit

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 93.65 (+1.63%)
Cortexyme to Present at Annual Biomarkers for Alzheimer's Disease Summit

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases,...

CRTX : 93.65 (+1.63%)
Another Busy Week of Earnings Coming Up

Monday U.S. Economic Lookahead Empire State manufacturing index (Aug) Featured Earnings JD.com, ...

JD : 73.98 (-2.82%)
FN : 106.45 (+0.17%)
CRTX : 93.65 (+1.63%)
WMT : 143.17 (+0.28%)
HD : 337.49 (+0.47%)
A : 172.40 (-0.21%)
NVDA : 220.81 (-1.78%)
CSCO : 56.73 (+0.07%)
LOW : 207.87 (-0.05%)
AMAT : 141.92 (+0.57%)
EL : 320.65 (-0.21%)
ROST : 115.99 (+0.37%)
DE : 349.25 (-0.64%)
UI : 305.49 (-0.02%)
FL : 48.23 (-7.16%)
DBM.TO : 6.73 (+2.12%)
FR.TO : 14.94 (-1.19%)
FN.TO : 44.16 (-0.20%)
VET.TO : 10.83 (+1.98%)
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

--Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021

CRTX : 93.65 (+1.63%)
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 93.65 (+1.63%)
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer's Disease at AAIC 2021

--Cortexyme to host AAIC symposium titled "Getting to the Root Cause of Alzheimer's Disease: An Innovative, Upstream Approach for Disease Modification" on Tuesday, July 27

CRTX : 93.65 (+1.63%)
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 93.65 (+1.63%)
Cortexyme to Present New Data at AAIC 2021

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative...

CRTX : 93.65 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States....

See More

Key Turning Points

3rd Resistance Point 99.24
2nd Resistance Point 96.78
1st Resistance Point 95.21
Last Price 93.65
1st Support Level 91.18
2nd Support Level 88.72
3rd Support Level 87.15

See More

52-Week High 121.98
Last Price 93.65
Fibonacci 61.8% 85.57
Fibonacci 50% 74.32
Fibonacci 38.2% 63.07
52-Week Low 26.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar